UK-based computational drug discovery firm, e-therapeutics, has secured £29m in funding, following its recent delisting from the AIM market. This funding round was led by M&G Investment Management and Richard Griffiths. Founded in 2001, e-therapeutics has leveraged computational and biological data to discover RNAi medicines. The new capital will support clinical trials and the enhancement of AI in its platform. Citing limited institutional interest and risk appetite in the UK, the company ceased trading on AIM on May 9 and now considers listing on NASDAQ. CEO Ali Mortazavi emphasized the limited UK engagement and the more favorable US markets, noting a broader gap in valuations between UK and US-listed firms.

Biotechnology, Financial Services, Technology,United Kingdom, United States

Biotech secures £29m after delisting from AIM market